Metiblo

Methylthioninium Chloride, the active ingredient in Metiblo, is a compound presented as an intravenous formulation for use under medical supervision. It is currently investigated for potential therapeutic applications but does not have an established drug class or approved indication. GNH USA supplies Metiblo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Metiblo contains methylthioninium chloride, a compound that is presently evaluated in clinical research rather than having established therapeutic indications.

Adverse reactions reported for Metiblo are limited, reflecting its investigational status.

Common Side Effects: - Injection site discomfort: mild pain or irritation at the site of intravenous administration. - Transient headache: short‑lasting headache reported in some subjects. - Nausea: occasional feeling of nausea during or after infusion.

Serious or Rare Side Effects: - Hypotension: sudden drop in blood pressure requiring monitoring. - Allergic reaction: rash, itching, or anaphylaxis in rare cases. - Hemolysis: potential red blood cell breakdown observed in isolated reports. - Renal impairment: decreased kidney function noted in limited instances.

Metiblo should be administered only by qualified healthcare professionals in a setting equipped for intravenous therapy. - Patient assessment: evaluate cardiovascular status before infusion. - Monitoring: observe vital signs and infusion site throughout administration. - Contraindications: avoid use in patients with known hypersensitivity to methylthioninium compounds. - Pregnancy: lack of adequate data; use only if potential benefit justifies potential risk. - Breastfeeding: insufficient information; consider discontinuation of breastfeeding. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Limited interaction data are available for methylthioninium chloride. Caution is advised when co‑administering with agents that affect hemodynamics or redox balance.

Major Interactions (Avoid): - Vasodilators: may exacerbate hypotensive effects. - Reducing agents: could alter the redox state of the compound.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding tendencies. - Nephrotoxic drugs: observe renal function. - Hepatotoxic drugs: assess liver enzymes. - Other intravenous dyes: potential additive toxicity. - Electrolyte-altering agents: watch for electrolyte disturbances.